JP2024504366A5 - - Google Patents
Info
- Publication number
- JP2024504366A5 JP2024504366A5 JP2023544294A JP2023544294A JP2024504366A5 JP 2024504366 A5 JP2024504366 A5 JP 2024504366A5 JP 2023544294 A JP2023544294 A JP 2023544294A JP 2023544294 A JP2023544294 A JP 2023544294A JP 2024504366 A5 JP2024504366 A5 JP 2024504366A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- syndrome
- items
- disease
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140488P | 2021-01-22 | 2021-01-22 | |
| US63/140,488 | 2021-01-22 | ||
| PCT/US2022/012739 WO2022159373A1 (en) | 2021-01-22 | 2022-01-18 | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504366A JP2024504366A (ja) | 2024-01-31 |
| JP2024504366A5 true JP2024504366A5 (https=) | 2025-01-27 |
Family
ID=80820704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544294A Pending JP2024504366A (ja) | 2021-01-22 | 2022-01-18 | 抗ｃ５抗体を使用して補体媒介血栓性微小血管障害症を治療する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240092881A1 (https=) |
| EP (2) | EP4281472A1 (https=) |
| JP (1) | JP2024504366A (https=) |
| KR (1) | KR20230134533A (https=) |
| AU (1) | AU2022210283A1 (https=) |
| CA (1) | CA3173016A1 (https=) |
| IL (1) | IL304593A (https=) |
| WO (1) | WO2022159373A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| EP4583911A1 (en) * | 2022-09-06 | 2025-07-16 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
| TW202426048A (zh) * | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| WO2014099546A1 (en) | 2012-12-19 | 2014-06-26 | Promerus, Llc | Process for the preparation of high purity norbornene alkanols and derivatives thereof |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| DK3658184T5 (da) * | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| EP3873602B1 (en) * | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| CN117838856A (zh) * | 2019-01-25 | 2024-04-09 | 亚力兄制药公司 | 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用 |
| EP3924380A1 (en) * | 2019-02-14 | 2021-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis |
| WO2021091937A1 (en) * | 2019-11-08 | 2021-05-14 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| CA3173011A1 (en) * | 2020-06-24 | 2021-12-30 | Alexion Pharmaceuticals, Inc. | Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions |
-
2022
- 2022-01-18 EP EP22704040.9A patent/EP4281472A1/en not_active Withdrawn
- 2022-01-18 KR KR1020237027849A patent/KR20230134533A/ko active Pending
- 2022-01-18 CA CA3173016A patent/CA3173016A1/en active Pending
- 2022-01-18 WO PCT/US2022/012739 patent/WO2022159373A1/en not_active Ceased
- 2022-01-18 EP EP24158584.3A patent/EP4378479A3/en active Pending
- 2022-01-18 JP JP2023544294A patent/JP2024504366A/ja active Pending
- 2022-01-18 US US18/272,906 patent/US20240092881A1/en active Pending
- 2022-01-18 AU AU2022210283A patent/AU2022210283A1/en active Pending
-
2023
- 2023-07-19 IL IL304593A patent/IL304593A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504366A5 (https=) | ||
| US20250002567A1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| JP2021167362A (ja) | 補体関連障害を処置するための方法および組成物 | |
| JP6013733B2 (ja) | Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ | |
| US11203628B2 (en) | CD200 mutants and its uses | |
| JP2020528894A5 (https=) | ||
| ES2769123T3 (es) | Anticuerpos de quimiocinas PAN ELR+ CXC | |
| JP2015526064A5 (https=) | ||
| JP2024518163A5 (https=) | ||
| JP2021525718A5 (https=) | ||
| WO2020097164A1 (en) | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same | |
| JP2024504366A (ja) | 抗ｃ５抗体を使用して補体媒介血栓性微小血管障害症を治療する方法 | |
| EP3454902A1 (en) | Anti-complement factor c4/c4b antibodies and uses thereof | |
| US12534527B2 (en) | KIR3DL3 is an inhibitory receptor of the immune system and uses thereof | |
| WO2025087363A1 (zh) | 用TACI-Fc融合蛋白治疗自身免疫性脑炎的方法 | |
| JP2020507569A5 (https=) | ||
| TW202525323A (zh) | 用ＴＡＣＩ－Ｆｃ融合蛋白治療ＡＮＣＡ相關性血管炎的方法 | |
| TW202229352A (zh) | 聯合治療及其使用方法 | |
| CN118681009A (zh) | 一种复方制剂及其应用 | |
| TW202525840A (zh) | 用ＴＡＣＩ－Ｆｃ融合蛋白治療抗體介導性排斥反應的方法 | |
| CN115611981A (zh) | 抗pd-1抗体在治疗外周t细胞淋巴瘤中的应用 | |
| Kamble et al. | Orthotopic heart transplant facilitated autologous hematopoietic stem cell transplantation in light-chain amyloidosis | |
| Kacani et al. | Detachment of HIV-1 from follicular dendritic cells by blocking the C3D-CR2 interaction | |
| Verschoor et al. | Local synthesis of C3 in lymphoid tissues is sufficient to restore humoral responses to peripheral herpes simplex virus (HSV-1) infection in C3-deficient mice | |
| Zhakhov et al. | Determination of the factor H in sera of HIV infected patients by anti-factor H monoclonal antibodies |